Skip to main content
GeneralHomeInvestorsNews

Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting

By July 1, 2024No Comments